证券代码：603387 证券简称：基蛋生物 公告编号：2025-014 本次会计政策变更前，公司执行财政部颁布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 （二）变更后采用的会计政策 基蛋生物科技股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会计政策变更是基蛋生物科技股份有限公司（以下简称"公司"） 根据法律法规和国家统一的会计制度的要求进行的变更，无需提交公司董事会和 股东大会审议，不会对公司的财务状况、经营成果和现金流量产生重大影响，不 存在损害公司及股东利益的情况。 一、会计政策变更情况概述 2024 年 3 月，财政部印发了《企业会计准则应用指南汇编 2024》，明确了关 于保证类质保费用的列报规定。2024 年 12 月，财政部发布了《企业会计准则解 释第 18 号》（财会〔2024〕24 号），规定对不属于单项履约义务的保证类质量保 证产生的预计负债，应当按确定的金额计入"主营业务成 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-012 基蛋生物科技股份有限公司 关于召开2024年年度股东大会通知公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 22 日 14 点 00 分 召开地点：南京市六合区沿江工业开发区博富路 9 号基蛋生物科技股份有限 公司四楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 22 日 至2025 年 5 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通 ...

基蛋生物科技股份有限公司监事会 2025 年 4 月 29 日 基蛋生物科技股份有限公司 监事会对《董事会关于 2024 年度非标准财务报告 审计意见涉及事项的专项说明》的意见 公证天业会计师事务所（特殊普通合伙）（以下简称"公证天业"）对基蛋生 物科技股份有限公司（以下简称"公司"）2024 年度财务报告出具了保留意见的 审计报告，公司董事会对该事项作出了专项说明。根据中国证券监督管理委员会 《公开发行证券的公司信息披露编报规则第 14 号——非标准审计意见及其涉及 事项的处理》和《上海证券交易所股票上市规则》等相关规定，监事会发表意见 如下： 监事会认为：公司董事会关于 2024 年度非标准财务报告审计意见涉及事项 的专项说明符合公司实际情况，同意公司董事会出具的《董事会关于 2024 年度 非标准财务报告审计意见涉及事项的专项说明》。监事会将持续关注、督促公司 董事会和管理层的应对工作，争取尽快消除所涉事项及其影响，切实维护上市公 司及全体投资者合法权益。 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-006 监事会认为：公司2024年年度报告及其摘要的编制和审议程序符合法律法规、《公 司章程》和公司内部管理制度的各项规定；公司2024年年度报告及其摘要的内容和格式 符合中国证券监督管理委员会和上海证券交易所的各项规定，所包含的信息公允地反映 了公司2024年度的财务状况、经营成果及其他重要事项；未发现参与公司2024年年度报 告编制和审议的人员有违反保密规定的行为。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)及《上海证券报》 披露的《基蛋生物：2024年年度报告》《基蛋生物：2024年年度报告摘要》。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届监事会第五次会议的通知 已于2025年4月16日以电子邮件的方式发出，通知了全体监事和其他列席人员。公司本 次监事会会议于2025年4月29日以通讯表决方式召开。会议应出席监事3人，实际出席监 事3人。会议由 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-005 一、董事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届董事会第五次会议的通知 已于 2025 年 4 月 16 日以电子邮件形式向全体董事、监事和高级管理人员发出。本次会 议于 2025 年 4 月 29 日以现场及通讯表决方式召开。会议应出席董事 9 人，实际出席董 事 9 人。本次会议由董事长苏恩本先生主持，公司全体监事和高级管理人员列席了本次 会议。本次会议的召开符合《中华人民共和国公司法》和《基蛋生物科技股份有限公司 章程》及有关法律法规的规定，会议决议合法有效。 二、董事会会议审议情况 （一）审议并通过《关于公司〈2024 年年度报告〉及其摘要的议案》 公司根据 2024 年度的实际经营情况和财务状况，依照有关规定编制《2024 年年度 报告》及其摘要。董事会审核后认为公司编制的 2024 年年度报告全文及其摘要，可以 全面、客观、真实地反映公司 2024 年度经营情况。具体内容详见公司同日在上海证券 交易所网站(www.sse.com.cn)及《上海证券报》披露的《基蛋生物：2024 年年度报告》 《基蛋生 ...

基蛋生物科技股份有限公司 第四届董事会独立董事专门会议第二次会议 基蛋生物科技股份有限公司 第四届董事会独立董事专门会议第二次会议决议 基蛋生物科技股份有限公司（以下简称"公司"）第四届董事会独立董事专 门会议第二次会议于 2025 年 4 月 22 日以现场及通讯表决方式召开。本次会议应 到独立董事 3 人：万遂人、鞠熀先、凌华，实到独立董事 3 人。会议由半数以上 独立董事推举鞠熀先先生主持。符合《中华人民共和国公司法》和《基蛋生物科 技股份有限公司章程》的规定。本次会议经过投票表决，通过了如下决议： 一、审议并通过《关于 2024 年度日常关联交易执行情况及 2025 年度日常 关联交易预计的议案》 我们认为：报告期内，公司发生的关联交易是根据公司正常经营所需，符合 公司的实际情况，遵循了公平、公正的市场原则；本次预计 2025 年度日常关联 交易是公司正常生产经营所需，定价公允合理，符合公平、公正原则，不存在损 害公司及全体股东利益的情况，对公司的独立性没有影响，不会导致公司对关联 人形成较大的依赖。同意将本议案提交公司董事会审议。 表决结果：同意 3 票、反对 0 票、弃权 0 票。 本议案尚需第四 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-007 基蛋生物科技股份有限公司 2024年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每10股派发现金红利0.9元（含税）。 1、公司拟向全体股东每 10 股派发现金红利 0.9 元（含税）。截至 2024 年 4 月 28 日，公司总股本 507,153,517 股，以此计算合计拟派发现金红利 45,643,816.53 元（含税）。本年度公司现金分红（包括中期已分配的现金红利） 总额 91,287,633.06 元，占本年度归属于上市公司股东净利润的比例为 40.82%。 2、如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股/ 回购股份/股权激励授予股份回购注销/重大资产重组股份回购注销等致使公司 总股本发生变动的，公司拟维持分配总额不变，相应调整每股分配比例。如后续 总股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交股东大会审议。 本次利润分配以实施权益分派股权登记日 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-016 基蛋生物科技股份有限公司 关于会计差错更正的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 基蛋生物科技股份有限公司（以下简称"基蛋生物"或"公司"）本次更 正内容为追溯调整 2024 年第三季度报告。 本次调整对 2024 年第三季度报告资产总额、所有者权益、归属于母公司 所有者权益、营业收入、净利润、归属于母公司净利润的影响金额具体如下： 单位：元 币种：人民币 | 项目 | 调整金额 | 调整比例 | | --- | --- | --- | | 资产总额 | -95,448,644.93 | -2.43% | | 所有者权益 | -88,173,974.70 | -3.19% | | 其中：归属于母公司所有者权益 | -26,865,709.49 | -1.03% | | 营业收入 | - | - | | 净利润 | -26,815,395.64 | -12.85% | | 其中：归属于母公司净利润 | -26,865,70 ...

Financial Performance - The company's operating revenue for the third quarter was ¥262,156,808.27, a decrease of 11.91% compared to the same period last year[4] - Net profit attributable to shareholders was ¥28,609,951.22, down 52.59% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥18,988,078.64, reflecting a decline of 65.47% compared to the previous year[4] - In the first three quarters of 2024, the company achieved operating revenue of CNY 880 million, a decrease of 12.10% year-on-year[15] - The net profit attributable to shareholders was CNY 175 million, down 23.42% compared to the same period last year[15] - Total operating revenue for the first three quarters of 2024 was ¥879,824,587.76, a decrease of 12.1% compared to ¥1,000,961,989.28 in the same period of 2023[23] - Net profit for the first three quarters of 2024 was ¥181,904,536.85, a decline of 22.2% from ¥233,662,791.59 in the previous year[24] - Total comprehensive income for the period was CNY 189,620,691.30, a decrease from CNY 234,143,463.91 in the previous year[25] Earnings and Shareholder Returns - Basic and diluted earnings per share were both ¥0.06, a decrease of 50.00% compared to the same period last year[4] - Basic and diluted earnings per share decreased to CNY 0.35 from CNY 0.45 year-over-year[25] - The weighted average return on equity decreased to 1.10%, down 1.32 percentage points year-on-year[4] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥249,907,045.22, an increase of 70.58%[4] - The cash and cash equivalents as of September 30, 2024, were CNY 536.59 million, up from CNY 484.33 million at the end of 2023[18] - The company's cash and cash equivalents decreased to ¥1,930,829,694.44 from ¥2,151,184,140.66 year-over-year[20] - Net cash flow from operating activities increased to CNY 249,907,045.22, compared to CNY 146,507,664.68 in the same period last year, representing a growth of 70.5%[28] - Cash inflow from operating activities totaled CNY 1,125,151,015.42, down from CNY 1,268,627,997.86, a decline of 11.3%[27] - Cash outflow from operating activities decreased to CNY 875,243,970.20 from CNY 1,122,120,333.18, a reduction of 22.0%[28] - Net cash flow from investing activities was negative at CNY -139,612,486.27, an improvement from CNY -349,098,239.79 in the previous year[28] - Cash flow from financing activities resulted in a net outflow of CNY -53,954,549.19, compared to CNY -38,940,372.59 last year[28] - The ending cash and cash equivalents balance increased to CNY 536,086,628.64 from CNY 407,471,086.12 year-over-year[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,839,310,398.65, an increase of 4.40% from the end of the previous year[5] - Total liabilities increased to ¥1,161,681,548.46, compared to ¥1,030,379,608.82 in the previous year[20] - The total owner's equity decreased slightly to ¥2,677,628,850.19 from ¥2,741,246,444.12 year-over-year[21] - The company reported a significant increase in long-term equity investments, rising to ¥122,870,201.52 from ¥50,873,981.61[20] Operational Highlights - The core product, Getein1600, had over 400 units installed in the first three quarters of 2024[15] - The sales revenue from the chemical luminescence line reached CNY 196 million, an increase of 38.43% year-on-year[15] - The overseas revenue from conventional products was CNY 84.99 million, a year-on-year increase of 20.31%[16] - The company installed over 710 units of the small luminescence product MAGICL6000 and MAGICL6000i in various hospitals[15] - The company has installed over 70 units of the Metis6000 fully automated biochemical immunoassay line since its launch[15] Non-Recurring Items - The company recognized government subsidies amounting to ¥6,537,901.80 during the reporting period, contributing positively to the financial results[8] - Non-recurring gains and losses totaled ¥9,621,913.14 for the current period, with a significant portion attributed to government subsidies and other income[9] Changes in Consolidation - The company has decided to no longer consolidate Wuhan Jingchuan Diagnostic Technology Co., Ltd. into its financial statements starting July 1, 2024[16]

Financial Performance - The company's operating revenue for 2024 was CNY 1,164,798,937.40, a decrease of 14.93% compared to CNY 1,369,162,256.52 in 2023[22]. - Net profit attributable to shareholders for 2024 was CNY 223,636,488.43, down 20.06% from CNY 279,771,914.08 in 2023[22]. - The basic earnings per share for 2024 was CNY 0.44, reflecting a decline of 20.00% from CNY 0.55 in 2023[23]. - The cash flow from operating activities increased by 26.94% to CNY 422,998,055.82 in 2024, compared to CNY 333,220,661.81 in 2023[24]. - The company's total assets at the end of 2024 were CNY 3,707,374,587.49, a decrease of 1.70% from CNY 3,771,626,052.94 at the end of 2023[22]. - The weighted average return on equity for 2024 was 8.64%, down from 11.17% in 2023, a decrease of 2.53 percentage points[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 202,042,109.65, a decrease of 16.33% from CNY 241,487,200.13 in 2023[22]. - The company reported a loss of CNY 8,087,939.59 from the disposal of non-current assets in 2024[29]. - The total cash dividends distributed during the reporting period amounted to RMB 91,287,633.06, representing 40.82% of the net profit attributable to shareholders of the listed company[6]. - The company achieved total revenue of CNY 1,164,798,937.40, a year-on-year decrease of 14.93%[79]. - The company's net profit attributable to shareholders was CNY 22,363.65 million, down 20.06% year-on-year[79]. Research and Development - The company invested 207 million RMB in R&D in 2024, focusing on chemiluminescence instruments, line systems, and core raw materials, resulting in 373 new patent authorizations[41]. - The company is focusing on R&D investments in molecular diagnostic systems and smart laboratories, integrating AI-assisted diagnostic technology with hardware[72]. - The company plans to continue increasing investment in R&D projects to enhance product performance and reduce production costs[43]. - The company has 497 R&D personnel, accounting for 25.53% of the total workforce[96]. - The company emphasizes continuous R&D innovation as a core driver, enhancing comprehensive innovation capabilities to expand terminal coverage in the clinical diagnostic market[70]. Product Development and Innovation - The company launched the fully automated biochemical analyzer CM800 with a throughput of 800 tests per hour, featuring 137 sample positions and 114 reagent positions[60]. - The Metis6000 fully automated biochemical immunoassay line was installed nearly 90 times in 2024, with a total of about 140 installations since its launch, 70% of which were in secondary and lower-level hospitals[36]. - The company has established eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular testing, expanding from low-throughput to high-throughput automated systems[57]. - The company has transitioned from a single POCT product line to a diverse product range, including chemiluminescence and biochemical products, and is expanding into both tiered hospitals and overseas markets[57]. - The company launched the GN7120 fully automatic nucleic acid amplification analyzer, enhancing its product matrix for small and medium hospitals[74]. Market Presence and Expansion - The company has expanded its overseas market presence to cover 130 countries and regions, establishing good cooperation with local distributors and healthcare institutions[64]. - The company plans to expand its overseas market presence, particularly promoting its small luminescence products MAGICL6000 and MAGICL6000i across Europe, Africa, Asia, and Latin America[116]. - The company has established over 2,000 product import licenses in 66 countries as of December 31, 2024, enhancing its international market presence[45]. - The overseas revenue from conventional products reached 137 million RMB, representing a year-on-year growth of 4.53%[44]. - The company has installed nearly 40 units of the CM-400 and approximately 70 units of the MAGICL6000 and MAGICL6000i in overseas markets, indicating strong growth potential[45]. Governance and Compliance - The company has established an independent financial department with a complete accounting system, ensuring financial independence[129]. - The company maintains independent operations with no shared bank accounts with controlling shareholders[130]. - The company has a complete and independent asset structure, with no instances of fund or asset occupation by controlling shareholders[128]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[127]. - The company has implemented internal control systems to ensure effective management of subsidiaries and mitigate operational risks[167]. Environmental and Social Responsibility - The company invested 512,300 RMB in environmental protection during the reporting period[172]. - The company ensures that wastewater meets the required standards before being discharged, with regular monitoring of water quality parameters[174]. - The company has implemented measures to control noise pollution, ensuring compliance with relevant noise emission standards[176]. - The company has established a hazardous waste storage facility that meets regulatory requirements and has signed agreements with qualified disposal companies for waste management[176]. - Total donations amounted to 724,000 CNY, with 668,200 CNY in cash contributions[179]. Shareholder Relations and Dividends - The company has committed to a three-year shareholder return plan for 2023-2025, which was approved in the extraordinary shareholder meeting[131]. - The total cash dividend amount for the current period is CNY 91,287,633.06, which represents 40.82% of the net profit attributable to ordinary shareholders[163]. - The company plans to distribute dividends in cash, stock, or a combination of both, with a minimum cash distribution of 10% of the distributable profit for the year if there are no major investment plans or cash expenditures[157]. - The cash dividend distribution ratio is set at a minimum of 80% for mature companies without major expenditures, 40% for mature companies with major expenditures, and 20% for growth-stage companies with major expenditures[158]. - Over the last three accounting years, the cumulative cash dividend amount is CNY 344,864,391.56, with an average annual net profit of CNY 334,106,127.64, resulting in a cash dividend ratio of 103.22%[165].